LOS ANGELES -- July 26, 2010 -- The Ministry of Health, Labor and Welfare in Japan has approved Abraxane IV Infusion 100 mg, Paclitaxel Injection (suspension with albumin) for use in the treatment of breast cancer. There are approximately 50,000 cases of breast cancer in Japan.
With the approval in Japan, Abraxane is now approved in 40 countries. Abraxane is also being developed in Japan for the treatment of lung and gastric cancers and...
– Product Launch Planned for September; ABRAXANE Now Approved in 40 Countries –
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE® IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment...
ecancermedicalscience
Published: 17/07/2010 11:14:27
By Dr Sharan Sharma
Regular nonsteroidal anti-inflammatory drug (NSAID) use can be a feasible way to prevent cancer in Helicobacter pylori infected gastric ulcer patients according to a new study that was published in June 20 issue of Journal of Clinical Oncology. Researchers from Taiwan did a nationwide retrospective cohort study using data from National Health Insurance database. They took 52,161 hospitalized peptic...
China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
BEIJING, July 15 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its HER-2 FISH probe has been chosen to be used in a research project focusing on cancer targeted therapy...
LONDON (Reuters) - Britain's health cost watchdog has rejected Roche's cancer drug Herceptin for patients with stomach cancer, which means they will not get the drug paid for by the country's taxpayer-funded National Health Service (NHS).
The National Institute for Health and Clinical Excellence (NICE) said Tuesday it was rejecting the drug, whose generic name is trastuzumab, for gastric cancer "due to the uncertainty surrounding...
